actinic keratosis
Dermatology · 2012–2014
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ingenol mebutate Treatment as field therapy of solar keratosis (actinic keratosis) of the face and scalp in adults. | Jul 2014 | Not recommended | input received |
| ingenol mebutate Field therapy for the treatment of solar keratoses of the face and scalp in patients who have had a previously diagnosed squamous cell carcinoma. | Nov 2013 | Not recommended | no section in document |
| ingenol mebutate Field treatment of solar (actinic) keratoses of the face and scalp in patients where topical fluorouracil 5% is clinically inappropriate. | Nov 2012 | Not recommended | unclear |
| ingenol mebutate Field treatment of solar (actinic) keratoses of the face and scalp in patients where topical fluorouracil 5% is clinically inappropriate. | Nov 2012 | Not recommended | unclear |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| tirbanibulinKLISYRI tirbanibulin 1% w/w ointment sachet | 2024 | 1 |
| fluorouracil + salicylic acidACTIKERALL fluorouracil and salicylic acid 0.5% / 10% (w/w) topical so | 2019 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.